Helen Kovari1, Bruno Ledergerber2, Matthias Cavassini3, Juan Ambrosioni4, Andrea Bregenzer5, Marcel Stöckle6, Enos Bernasconi7, Roger Kouyos8, Rainer Weber2, Andri Rauch9. 1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Switzerland. Electronic address: helen.kovari@usz.ch. 2. Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Switzerland. 3. Division of Infectious Diseases, University Hospital, Lausanne, Switzerland. 4. Division of Infectious Diseases, University Hospital, Geneva, Switzerland. 5. Division of Infectious Diseases, Cantonal Hospital, St. Gall, Switzerland. 6. Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basle, Switzerland. 7. Ospedale Regionale, Lugano, Switzerland. 8. Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Switzerland. 9. University Clinic of Infectious Diseases, University Hospital Berne and University of Berne, Berne, Switzerland.
Abstract
BACKGROUND & AIMS: The landscape of HCV treatments is changing dramatically. At the beginning of this new era, we highlight the challenges for HCV therapy by assessing the long-term epidemiological trends in treatment uptake, efficacy and mortality among HIV/HCV-coinfected people since the availability of HCV therapy. METHODS: We included all SHCS participants with detectable HCV RNA between 2001 and 2013. To identify predictors for treatment uptake uni- and multivariable Poisson regression models were applied. We further used survival analyses with Kaplan-Meier curves and Cox regression with drop-out as competing risk. RESULTS: Of 12,401 participants 2107 (17%) were HCV RNA positive. Of those, 636 (30%) started treatment with an incidence of 5.8/100 person years (PY) (95% CI 5.3-6.2). Sustained virological response (SVR) with pegylated interferon/ribavirin was achieved in 50% of treated patients, representing 15% of all participants with replicating HCV-infection. 344 of 2107 (16%) HCV RNA positive persons died, 59% from extrahepatic causes. Mortality/100 PY was 2.9 (95% CI 2.6-3.2) in untreated patients, 1.3 (1.0-1.8) in those treated with failure, and 0.6 (0.4-1.0) in patients with SVR. In 2013, 869/2107 (41%) participants remained HCV RNA positive. CONCLUSIONS: Over the last 13 years HCV treatment uptake was low and by the end of 2013, a large number of persons remain to be treated. Mortality was high, particularly in untreated patients, and mainly due to non-liver-related causes. Accordingly, in HIV/HCV-coinfected patients, integrative care including the diagnosis and therapy of somatic and psychiatric disorders is important to achieve mortality rates similar to HIV-monoinfected patients.
BACKGROUND & AIMS: The landscape of HCV treatments is changing dramatically. At the beginning of this new era, we highlight the challenges for HCV therapy by assessing the long-term epidemiological trends in treatment uptake, efficacy and mortality among HIV/HCV-coinfectedpeople since the availability of HCV therapy. METHODS: We included all SHCS participants with detectable HCV RNA between 2001 and 2013. To identify predictors for treatment uptake uni- and multivariable Poisson regression models were applied. We further used survival analyses with Kaplan-Meier curves and Cox regression with drop-out as competing risk. RESULTS: Of 12,401 participants 2107 (17%) were HCV RNA positive. Of those, 636 (30%) started treatment with an incidence of 5.8/100 person years (PY) (95% CI 5.3-6.2). Sustained virological response (SVR) with pegylated interferon/ribavirin was achieved in 50% of treated patients, representing 15% of all participants with replicating HCV-infection. 344 of 2107 (16%) HCV RNA positive persons died, 59% from extrahepatic causes. Mortality/100 PY was 2.9 (95% CI 2.6-3.2) in untreated patients, 1.3 (1.0-1.8) in those treated with failure, and 0.6 (0.4-1.0) in patients with SVR. In 2013, 869/2107 (41%) participants remained HCV RNA positive. CONCLUSIONS: Over the last 13 years HCV treatment uptake was low and by the end of 2013, a large number of persons remain to be treated. Mortality was high, particularly in untreated patients, and mainly due to non-liver-related causes. Accordingly, in HIV/HCV-coinfectedpatients, integrative care including the diagnosis and therapy of somatic and psychiatric disorders is important to achieve mortality rates similar to HIV-monoinfectedpatients.
Authors: Rainer Puhr; Stephen T Wright; Jennifer F Hoy; David J Templeton; Nicolas Durier; Gail V Matthews; Darren Russell; Matthew G Law Journal: Sex Health Date: 2017-08 Impact factor: 2.706
Authors: Marina B Klein; Keri N Althoff; Yuezhou Jing; Bryan Lau; Mari Kitahata; Vincent Lo Re; Gregory D Kirk; Mark Hull; H Nina Kim; Giada Sebastiani; Erica E M Moodie; Michael J Silverberg; Timothy R Sterling; Jennifer E Thorne; Angela Cescon; Sonia Napravnik; Joe Eron; M John Gill; Amy Justice; Marion G Peters; James J Goedert; Angel Mayor; Chloe L Thio; Edward R Cachay; Richard Moore Journal: Clin Infect Dis Date: 2016-08-09 Impact factor: 9.079
Authors: Kenneth E Sherman; Minhee Kang; Richard Sterling; Triin Umbleja; Kristen Marks; Jennifer J Kiser; Beverly Alston-Smith; Wayne Greaves; Adeel A Butt Journal: World J Hepatol Date: 2017-02-08
Authors: Justyna D Kowalska; Grzegorz Wójcik; Jakub Rutkowski; Magdalena Ankiersztejn-Bartczak; Ewa Siewaszewicz Journal: PLoS One Date: 2017-11-13 Impact factor: 3.240
Authors: Victor Virlogeux; Fabien Zoulim; Pascal Pugliese; Isabelle Poizot-Martin; Marc-Antoine Valantin; Lise Cuzin; Jacques Reynes; Eric Billaud; Thomas Huleux; Firouze Bani-Sadr; David Rey; Anne Frésard; Christine Jacomet; Claudine Duvivier; Antoine Cheret; Laurent Hustache-Mathieu; Bruno Hoen; André Cabié; Laurent Cotte Journal: BMC Med Date: 2017-12-18 Impact factor: 8.775